We are focused on leading innovative technology and emerging company opportunities in the biotech, gene-therapy, non-opiate pain and pharma/therapeutic spaces. Our record of success and breadth of expertise in these arenas has followed from our extensive network, alliance with leading innovators and CEOs, and an active approach to investing with thorough due-diligence and capital strength.
John D. Harkey, Jr. has over 25 years' experience as a private investor, chief executive and director in both public and private companies. He has merged, acquired, operated and/or served on the board of directors of eight public companies in biotech, energy, technology, aerospace, telecom, and restaurants, and private companies in healthcare, real estate, farm and ranch products and software. He is the Founder and Principal of JDH Investment Management, LLC, which is focused on leading innovative technologies and emerging company opportunities in biotech, gene therapy, non-opiate pain and pharma/therapeutic spaces. He is co-founder and formerly Executive Chairman of the Board of AveXis, Inc. (NASDAQ:AVXS), which was acquired in 2018 by Novartis. AveXis develops proprietary gene therapies for rare neurological genetic diseases. He also is a lead investor and serves on the board of CerSci Pharmaceuticals, which has a primary compound in Phase I trials for a non-opioid severe pain reliever. He is also a co-founder and currently serves on the board of Cessation Therapeutics. He is also Chairman of the Board of Dialectic Therapeutics, Inc. He previously served nine years on the Board of Directors of the Baylor Health Care System Foundation. He is formerly the Chairman of the Board of Regency Gas Partners, L.P. (NYSE:RGP, sold to Energy Transfer for $18 billion) and has served on the Board of Directors of the Energy Transfer, LP companies (NYSE: ET). He currently serves on the Board of Directors of Loral Space & Communications, Inc. (NASDAQ:LORL), and on the Board of Directors of Emisphere Technologies, Inc. (NASDAQ:EMIS). He formerly served on Board of Directors of Leap Wireless International, Inc. (NASDAQ:LEAP), which was acquired by AT&T for $4.1 billion. Mr. Harkey also serves as Chairman and Chief Executive Officer of Consolidated Restaurant Companies, Inc. Philanthropically, he serves on the board of The University of Texas Chancellor's Council and Vice Chair of the McCombs School of Business Advisory Board. He is also on the board of the Circle Ten Council of the Boy Scouts of America and former Chapter Chair of the Young President's Organization Dallas Gold Chapter. Mr. Harkey grew up in Brownwood, Texas, obtained a B.B.A. in Business Honors and a J.D. from the University of Texas at Austin and an M.B.A. from Stanford University School of Business.
Dr. David Genecov is a dedicated physician in the field of Cleft Lip and Palate, Craniofacial and Pediatric Plastic Surgery. A 4th generation Texan, he graduated from the Plan II Program at the University of Texas at Austin (1985). David began his medical education at the University of Texas Health Science Center in San Antonio (1990) and then completed residencies in General Surgery at West Virginia University (1995) and in Plastic Surgery at Wake Forest University (1997). Dr. Genecov completed fellowship training in Craniofacial Surgery at the International Craniofacial Institute, where he is now the director and owner. He is an adjunct associate professor at Baylor College of Dentistry at the Texas A&M Health Science Center and teaches residents and graduate students about cleft lip and palate and craniofacial surgery. His research has been centered on cranial bone regeneration, three dimensional surgical planning techniques, and the use of stem cells in reconstructive plastic surgery. He has been recognized for his medical service by Dallas Chapter of Hadassah, The Bnai Zion Foundation, D Magazine, Texas Monthly, Consumer Choice Awards and DFW Alliance for Healthcare Excellence. Dr. Genecov maintains American Board of Medical Specialties board certificates in plastic and reconstructive surgery.
Dr. Genecov founded or co-founded numerous companies in the health care space including AveXis (AVXS – Nasdaq), Skin Within, Inc., Synergy Surgical Services LLC, eCosmetic LLC and Biolife Cell Bank LLC. He currently a director of a Dallas pharmaceutical start-up, CerSci Therapeutics. He is the cofounder, CEO and President of Dialectic Therapeutics, an early stage oncology therapy company. He is a director and cofounder of Cessation Therapeutics, a start up biotechnology company in the substance use disorder space.
Dr. Genecov is involved civically in many ways. He currently serves as a trustee at St. Mark's School of Texas where he is chairman of the Education Committee and also serves on the Executive Committee. He is on the Plan II Visiting Committee, the College of Liberal Arts Advisory Board, and the Chancellor's Executive Committee, all at the University of Texas at Austin. He is a director at the Dallas Opera and serves on the PTECH Advisory Board of the Dallas Independent School District. Along with his wife, Lisa, their philanthropic efforts are focused on education and children's healthcare initiatives. He has also been honored for his philanthropic efforts by the Dallas Jewish Historical Society.
Dr. Genecov lives in Dallas with his wife, Dr. Lisa W. Genecov. Together they have 4 children, Michael, Max, Matthew and Megan. His hobbies include golf, hunting, fly fishing, and skiing. Dr. Genecov has completed 5 Ironman long distance races, including the World Championships in Kona, Hawaii.